--- title: "TXG 10x Genomics" canonical: "https://supercyclehq.com/stock/10x-genomics" type: "stock" dataAsOf: "2026-11-06" ticker: "TXG" license: "Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset." disclaimer: "Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI." --- # 10x Genomics (TXG) 10x Genomics is a life sciences tools company. ## AI Exposure Score **12/100, Peripheral.** 10x Genomics sells single cell and spatial biology instruments and consumables to researchers, with AI powering the analysis software. Value tracks life science tools demand and instrument placements, with AI as an enabling feature rather than the driver. ## Quote | Field | Value | | --- | --- | | Price (EOD close) | $59.28 | | Change 1d | +2.10% | | Change 7d | -15.45% | | Change 30d | -23.29% | | Change 1y | +288.72% | | 52-week high | $97.74 | | 52-week low | $15.25 | | Market cap | $7.7B | | P/E | n/a | | EPS | $-0.59 | | Next earnings | 2026-11-05 | Quote as of 2026-11-06. ## Company | Field | Value | | --- | --- | | Exchange | NASDAQ | | Sector | Healthcare | | Headquarters | Pleasanton, California | | CEO | Serge Saxonov | | Employees | 1,178 | | Website | https://www.10xgenomics.com | | Buildout layers | [AI Healthcare](https://supercyclehq.com/category/ai-healthcare) | ## What the company does 10x Genomics is a life sciences tools company. It sells instruments and consumables for single-cell and spatial biology, which let researchers study biological systems cell by cell. Revenue comes from instrument placements and the recurring consumables those instruments use. AI powers the analysis side of its platforms. Products include Chromium for single-cell analysis, Visium for spatial biology, Xenium with AI-driven analysis, and the Cell Ranger software pipeline. The AI software turns raw experimental data into biological insight for researchers. Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics trades on the NASDAQ, employs roughly 1,200 people, and is led by CEO Serge Saxonov. ## Role in the AI buildout 10x Genomics sits in the AI Healthcare layer as a research tools maker whose software depends on AI. Its instruments generate huge biological datasets, and AI analysis in tools like Xenium and Cell Ranger is what makes those datasets useful. That said, the company's results track life science research budgets and instrument demand, with AI as an enabling feature rather than the driver. Supercycle scores its AI exposure at 12 out of 100. ## Tracked investors holding it (13F) | Investor | Fund | Position value | Portfolio % | Change | Period | | --- | --- | --- | --- | --- | --- | | [Cathie Wood](https://supercyclehq.com/investors/cathie-wood) | ARK Investment Management | $383.5M | 2.49% | trimmed | 2026-06-30 | | [Stanley Druckenmiller](https://supercyclehq.com/investors/stanley-druckenmiller) | Duquesne Family Office | $15.5M | 0.35% | new | 2026-06-30 | | [Ray Dalio](https://supercyclehq.com/investors/ray-dalio) | Bridgewater Associates | $512,798 | 0.00% | trimmed | 2026-06-30 | ## Recent news - [10x Genomics Inc (TXG) (Q3 2026) Earnings Call Highlights: Atera Launch Takes Flight as Revenue ...](https://finance.yahoo.com/healthcare/articles/10x-genomics-inc-txg-q3-171349479.html?.tsrc=rss) (source, 2026-11-06) - [10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis](https://finance.yahoo.com/technology/ai/articles/10x-genomics-launches-sentira-ai-155400677.html?.tsrc=rss) (source, 2026-11-06) - [What 10x Genomics (TXG) Said on Its Q3 Earnings Call](https://www.marketbeat.com/instant-alerts/transcript-what-10x-genomics-txg-said-on-its-q3-earnings-call-2026-11-06/?utm_source=yahoofinance&utm_medium=yahoofinance&.tsrc=rss) (source, 2026-11-06) - [10x Genomics (TXG) Q3 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/11/06/10x-genomics-txg-q3-2026-earnings-call-transcript/?.tsrc=rss) (source, 2026-11-06) - [Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics](https://finance.yahoo.com/markets/stocks/articles/compared-estimates-10x-genomics-txg-233003630.html?.tsrc=rss) (source, 2026-11-05) ## FAQ ### What does 10x Genomics do? 10x Genomics sells single-cell and spatial biology instruments and consumables to researchers. Its platforms, including Chromium, Visium, and Xenium, help scientists study complex biological systems, with AI powering the analysis software. ### How is 10x Genomics exposed to AI? Lightly. Supercycle scores it 12 out of 100. AI is central to its analysis software, but revenue tracks life science tools demand and instrument placements, so AI is an enabling feature rather than the growth driver. ### What are 10x Genomics' main products? Chromium for single-cell analysis, Visium for spatial biology, Xenium with AI-driven analysis, and the Cell Ranger software pipeline. Instruments generate the data and the AI software interprets it for researchers. ### Where is 10x Genomics headquartered and who leads it? 10x Genomics is headquartered in Pleasanton, California, and led by CEO Serge Saxonov. The company was founded in 2012, trades on the NASDAQ, and employs roughly 1,200 people. --- Source: https://supercyclehq.com/stock/10x-genomics. Data as of 2026-11-06. Prices are end-of-day closes, never live. Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI. Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset.